Literature DB >> 23549671

Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Sabine Weninger1, Joris H De Maeyer, Romain A Lefebvre.   

Abstract

Our objective was to investigate the role of phosphodiesterase (PDE)3 and PDE4 and cGMP in the control of cAMP metabolism and of phosphorylation of troponin I (TnI) and phospholamban (PLB) when 5-HT4 receptors are activated in pig left atrium. Electrically paced porcine left atrial muscles, mounted in organ baths, received stimulators of particulate guanylyl cyclase (pGC) or soluble guanylyl cyclase (sGC) and/or specific PDE inhibitors followed by 5-HT or the 5-HT4 receptor agonist prucalopride. Muscles were freeze-clamped at different moments of exposure to measure phosphorylation of the cAMP/protein kinase A targets TnI and PLB by immunoblotting and cAMP levels by enzyme immunoassay. Corresponding with the functional results, 5-HT only transiently increased cAMP content, but caused a less quickly declining phosphorylation of PLB and did not significantly change TnI phosphorylation. Under combined PDE3 and PDE4 inhibition, the 5-HT-induced increase in cAMP levels and PLB phosphorylation was enhanced and sustained, and TnI phosphorylation was now also increased. Responses to prucalopride per se and the influence thereupon of PDE3 and PDE4 inhibition were similar except that responses were generally smaller. Stimulation of pGC together with PDE4 inhibition increased 5-HT-induced PLB phosphorylation compared to 5-HT alone, consistent with functional responses. sGC stimulation hastened the fade of inotropic responses to 5-HT, while cAMP levels were not altered. PDE3 and PDE4 control the cAMP response to 5-HT4 receptor activation, causing a dampening of downstream signalling. Stimulation of pGC is able to enhance inotropic responses to 5-HT by increasing cAMP levels, while sGC stimulation decreases contraction to 5-HT cAMP independently.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549671     DOI: 10.1007/s00210-013-0855-2

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  43 in total

1.  Protein dephosphorylation rates in myocytes after isoproterenol withdrawal.

Authors:  P M Stemmer; T H Ledyard; A M Watanabe
Journal:  Biochem Pharmacol       Date:  2000-06-15       Impact factor: 5.858

2.  PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts.

Authors:  S O Marx; S Reiken; Y Hisamatsu; T Jayaraman; D Burkhoff; N Rosemblit; A R Marks
Journal:  Cell       Date:  2000-05-12       Impact factor: 41.582

Review 3.  5-HT(4) receptors, a place in the sun: act two.

Authors:  Joël Bockaert; Sylvie Claeysen; Valérie Compan; Aline Dumuis
Journal:  Curr Opin Pharmacol       Date:  2011-02-20       Impact factor: 5.547

4.  Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle.

Authors:  L Raeymaekers; F Hofmann; R Casteels
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

Review 5.  Regulation of cardiac contractile function by troponin I phosphorylation.

Authors:  Joanne Layland; R John Solaro; Ajay M Shah
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

Review 6.  Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases.

Authors:  Rodolphe Fischmeister; Liliana R V Castro; Aniella Abi-Gerges; Francesca Rochais; Jonas Jurevicius; Jérôme Leroy; Grégoire Vandecasteele
Journal:  Circ Res       Date:  2006-10-13       Impact factor: 17.367

7.  A 5-HT4-like receptor in human left atrium.

Authors:  L Sanders; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-04       Impact factor: 3.000

8.  Phosphorylation of C-protein, troponin I and phospholamban in isolated rabbit hearts.

Authors:  J L Garvey; E G Kranias; R J Solaro
Journal:  Biochem J       Date:  1988-02-01       Impact factor: 3.857

9.  Ontogenic changes of the control by phosphodiesterase-3 and -4 of 5-HT responses in porcine heart and relevance to human atrial 5-HT(4) receptors.

Authors:  Alejandro Galindo-Tovar; Maria Luisa Vargas; Elisa Escudero; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

10.  Phosphorylation of phospholamban and troponin I through 5-HT4 receptors in the isolated human atrium.

Authors:  Ulrich Gergs; Joachim Neumann; Andreas Simm; Rolf-Edgar Silber; Freerk Ole Remmers; Stephanie Läer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-11-11       Impact factor: 3.000

View more
  6 in total

1.  Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice.

Authors:  Nicolas Keller; Stefan Dhein; Joachim Neumann; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-09       Impact factor: 3.000

2.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

3.  Identification of small molecule NPR-B antagonists by high throughput screening--potential use in heart failure.

Authors:  Trond Bach; Stine Bergholtz; Jon Riise; Eirik Qvigstad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-12-03       Impact factor: 3.000

4.  Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.

Authors:  Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-01-15       Impact factor: 3.000

5.  Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility.

Authors:  Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-07       Impact factor: 3.000

Review 6.  Phosphodiesterases and Compartmentation of cAMP and cGMP Signaling in Regulation of Cardiac Contractility in Normal and Failing Hearts.

Authors:  Gaia Calamera; Lise Román Moltzau; Finn Olav Levy; Kjetil Wessel Andressen
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.